News & Articles

Development of neurological and mental health drugs often requires pre-clinical testing in multiple pre-clinical models to demonstrate efficacy and safety and to elucidate mechanisms. Drug delivery to the central nervous system (CNS) to target neurological diseases is particularly problematic because the blood-brain barrier (BBB) prevents most compounds from reaching the...

On April 8th, Impel's director of business development, Paul Jenkins, will be presenting a talk on "Intranasal Insulin for the Treatment of Alzheimer’s Disease" at the Nasal Drug Delivery Conference in London. His presentation is on April 8 at 11:30 am in the Nose-to-brain Transport session....

On April 6 Impel CSO, John Hoekman will be presenting a talk on "Intranasal Insulin for the Treatment of Alzheimer’s Disease" at the Neurotech conference in Boston. His talk will be on April 6 at 10:30 at the Treatments for Alzheimer's and Cognitive Disorders session.  ...

The Centre for Addiction and Mental Health (CAMH) and Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression. This novel treatment is a peptide that disrupts two dopamine receptors that bind at higher rates in the brains of people...

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Now in its...

When: January 11, 2016 – January 14, 2016 (all-day) Where: San Francisco, CA, USA Calendar: Healthcare Investor Conferences ...